date,title,source
Oct-19-18,Innovate Biopharmaceuticals adds $5.2M to its coffers,American City Business Journals
Oct-29-18,Innovate Biopharmaceuticals Announces Positive Effect of Larazotide Acetate on reducing Intestinal Permeability in a NASH Preclinical Study,GlobeNewswire
Oct-31-18,Innovate Biopharmaceuticals Announces Participation at the Jefferies 2018 London Healthcare Conference,GlobeNewswire
Nov-05-18,"Innovate Biopharmaceuticals Announces Presentation at the BIO-Europe Conference, Copenhagen 2018 - 24th Annual Partnering Conference",GlobeNewswire
Nov-12-18,Sanyal Biotechnology and Innovate Biopharmaceuticals Present Data at AASLD Validating a Proprietary Leaky Gut Assay Demonstrating Reduced Intestinal Permeability with Larazotide Acetate Treatment in a NASH Preclinical Study,GlobeNewswire
Nov-13-18,Innovate Biopharmaceuticals Reports Third Quarter 2018 Earnings and Key Corporate Highlights,GlobeNewswire
Nov-26-18,"Innovate Biopharmaceuticals Strengthens Clinical Development with the Addition of Patrick H. Griffin, M.D., F.A.C.P.",GlobeNewswire
Dec-04-18,"Innovate Biopharmaceuticals Enters into a Collaboration with Massachusetts General Hospital and Announces Capital Update for the Celiac Disease Clinical Program and its NASH Development Strategy on December 17, 2018",GlobeNewswire
Dec-11-18,Today's Research Reports on Trending Tickers: Teva Pharmaceutical and Innovate Biopharmaceuticals,ACCESSWIRE
Dec-14-18,Healthcare Stocks That Could Weather the Market Volatility,ACCESSWIRE
Dec-17-18,Innovate Biopharmaceuticals Plans to Commence the First Ever Phase 3 Registration Trial in Celiac Disease in 1H 2019 and Announce Top-line NASH Data with Drug Combinations by EASL 2019,GlobeNewswire
Dec-17-18,Today's Research Reports on Trending Tickers: Innovate Biopharmaceuticals and Tenet Healthcare,ACCESSWIRE
Dec-25-18,"Could Innovate Biopharmaceuticals, Inc.s (NASDAQ:INNT) Investor Composition Influence The Stock Price?",Simply Wall St.
Feb-07-19,Innovate Biopharmaceuticals Announces Presentation at BIO CEO & Investor Conference,GlobeNewswire
Feb-22-19,Innovate Biopharmaceuticals Announces a New Chief Executive Officer and Chief Medical Officer,GlobeNewswire
Feb-25-19,Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts Focusing on the Molecular Biology and Pharmacology of Larazotide for the 2019 Digestive Disease Week Conference,GlobeNewswire
Feb-26-19,Innovate Biopharmaceuticals Schedules Conference Call to Provide Corporate and Operational Progress Updates,GlobeNewswire
Mar-01-19,"Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 14, 2019",GlobeNewswire
Mar-13-19,"Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 18, 2019",GlobeNewswire
Mar-18-19,"Innovate Biopharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 19, 2019",GlobeNewswire
Mar-18-19,Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement to Fund Initiation of the First Phase 3 Celiac Disease Clinical Trial,GlobeNewswire
Mar-19-19,"Innovate Biopharmaceuticals Reports Financing to Initiate the First Phase 3 Clinical Trial in Celiac Disease, Fiscal Year 2018 Earnings and Key Corporate Highlights",GlobeNewswire
Mar-20-19,"Innovate Biopharma raises more cash, chases treatment for celiac disease",American City Business Journals
Mar-26-19,Innovate Biopharmaceuticals Announces Collaboration with Institut Gustave Roussy to Study Regulation of Intestinal Permeability and the Gut Microbiota using Larazotide in Immuno-oncology Checkpoint Inhibitor Failure Pre-Clinical Models,GlobeNewswire
Apr-02-19,"Innovate Biopharmaceuticals to Announce First Quarter 2019 Financial Results and to Provide Operational Progress Updates on April 29, 2019",GlobeNewswire
Apr-11-19,Innovate Biopharmaceuticals Presents Oral Poster at European Association for the Study of the Liver (EASL) Demonstrating Positive Effect of Larazotide on Reduced Intestinal Permeability in a NASH Preclinical Study,GlobeNewswire
Apr-26-19,Innovate Biopharmaceuticals First Quarter 2019 Financial Results and Operational Progress Updates - Webcast Details,GlobeNewswire
Apr-29-19,Roller-coaster ride for Innovate's stock on Wall Street Monday,American City Business Journals
Apr-29-19,Innovate Biopharmaceuticals Announces $8.7 Million Registered Direct Offering Priced At-the-Market,GlobeNewswire
Apr-29-19,Edited Transcript of INNT earnings conference call or presentation 29-Apr-19 12:00pm GMT,Thomson Reuters StreetEvents
Apr-29-19,"Innovate Biopharmaceuticals Shows Larazotide is the First Drug, with its Novel Mechanism of Action of Re-normalizing the Intestinal Barrier, to Demonstrate Improvements in validated NASH Biomarkers and Endpoints in synergy with obeticholic acid, an FXR agonist, and Reports key first quarter 2019 financial results and operational highlights",GlobeNewswire
May-01-19,Innovate Biopharmaceuticals Announces Closing of $8.7 Million Registered Direct Offering,GlobeNewswire
May-01-19,Edited Transcript of INNT earnings conference call or presentation 29-Apr-19 12:00pm GMT,Thomson Reuters StreetEvents
May-09-19,"Innovate Biopharma Announces Analyst Event on Monday, May 20, 2019, in San Diego",GlobeNewswire
